AU4156197A - Oligonucleotide prodrugs - Google Patents

Oligonucleotide prodrugs

Info

Publication number
AU4156197A
AU4156197A AU41561/97A AU4156197A AU4156197A AU 4156197 A AU4156197 A AU 4156197A AU 41561/97 A AU41561/97 A AU 41561/97A AU 4156197 A AU4156197 A AU 4156197A AU 4156197 A AU4156197 A AU 4156197A
Authority
AU
Australia
Prior art keywords
oligonucleotide prodrugs
prodrugs
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41561/97A
Inventor
Sudhir Agrawal
Theresa Devlin
Radhakrishnan P Iyer
Dong Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of AU4156197A publication Critical patent/AU4156197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU41561/97A 1996-08-21 1997-08-21 Oligonucleotide prodrugs Abandoned AU4156197A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2426296P 1996-08-21 1996-08-21
US60024262 1996-08-21
PCT/US1997/014751 WO1998007734A1 (en) 1996-08-21 1997-08-21 Oligonucleotide prodrugs

Publications (1)

Publication Number Publication Date
AU4156197A true AU4156197A (en) 1998-03-06

Family

ID=21819691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41561/97A Abandoned AU4156197A (en) 1996-08-21 1997-08-21 Oligonucleotide prodrugs

Country Status (2)

Country Link
AU (1) AU4156197A (en)
WO (1) WO1998007734A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030558A1 (en) 2000-04-19 2003-08-27 Schering Corp MACROCICLIC COMPOUNDS, WHICH INCLUDE ENANTIOMERS, STEROISOMERS, ROTAMERS AND TAUTOMEROS, SALTS AND PHARMACEUTICALLY ACCEPTABLE SOLVATOS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THE PREPARATION AND THE USE OF SUCH COMPUTERS FOR THE INHIBITION, THE SERIES
DE60141608D1 (en) 2000-07-21 2010-04-29 Dendreon Corp PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
US6911428B2 (en) 2000-12-12 2005-06-28 Schering Corporation Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1487851A2 (en) * 2002-03-15 2004-12-22 Nuevolution A/S A building block capable of functional entity transfer to nucleophil
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN102123716B (en) 2008-04-03 2013-09-18 春堤公司 Compositions and methods for treating viral infections
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
CA2747999A1 (en) * 2008-12-23 2010-07-01 Girindus America, Inc. Sulfurizing reagents and their use for oligonucleotides synthesis
US9744183B2 (en) * 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
KR20140068884A (en) 2011-07-19 2014-06-09 웨이브 라이프 사이언시스 피티이. 리미티드 Methods for the synthesis of functionalized nucleic acids
JP6268157B2 (en) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan Asymmetric auxiliary group
CN112007045A (en) 2012-07-13 2020-12-01 波涛生命科学有限公司 Chiral control
MX356830B (en) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Chiral nucleic acid adjuvant.
IN2015DN01765A (en) 2012-08-20 2015-05-29 Univ California
JPWO2015108047A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
PL3094728T3 (en) 2014-01-16 2022-07-04 Wave Life Sciences Ltd. Chiral design

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547569A (en) * 1982-11-24 1985-10-15 The United States Of America As Represented By The Department Of Health And Human Services Intercalating agents specifying nucleotides
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
EP0652890B1 (en) * 1992-07-27 1998-01-14 HYBRIDON, Inc. Oligonucleotide alkylphosphonothioates
FR2705099B1 (en) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Phosphorothioate triester oligonucleotides and process for their preparation.
ATE202569T1 (en) * 1994-09-07 2001-07-15 Hybridon Inc PRODRUG OLIGONUCLEOTIDES
AU5319396A (en) * 1995-03-23 1996-10-08 Hybridon, Inc. Thiono triester modified antisense oligodeoxynucleotide phosphorothioates

Also Published As

Publication number Publication date
WO1998007734A1 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
AU2360195A (en) Oligonucleotide repeat arrays
AU1623299A (en) Nucleotide-based prodrugs
AU4040197A (en) Microturbomachinery
AU3387997A (en) Autonotification
AU4156197A (en) Oligonucleotide prodrugs
AU4013397A (en) Arylalkanoylpyridazines
AU4176997A (en) 3-alkyl-3-phenyl-piperidines
AU2684197A (en) Handleset
AU5259498A (en) Antisense oligonucleotides
AU4218597A (en) Superseat
AU3340797A (en) Modified oligonucleotides
AU2786295A (en) Spacing member
AU7918398A (en) Oligonucleotide derivatives
AU2090897A (en) Hydroxyhexahydropyridazines
AU5697699A (en) Oligonucleotide protecting groups
AU1907095A (en) Spacing member
AU3130597A (en) Tristetraprolin
AU5310500A (en) Pseudomycin prodrugs
AU3782797A (en) Printer
AU2237197A (en) Fishing-lure
AU4332497A (en) Endo-beta-galactosidase
AU1900097A (en) Cremators
AUPO894297A0 (en) A distribution system
AU1597197A (en) Thienoquinolines
AU3557397A (en) Double-tau-profile